Loading…
Rallybio Corporation is projected to rise to $18.94 by 2027, a +20% move from its current price of $15.73. RLYB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $15.41 | $15.73 | $16.06 | +0.01% |
| Jul 14 | $15.28 | $15.73 | $16.20 | +0.03% |
| Jul 15 | $15.19 | $15.74 | $16.31 | +0.04% |
| Jul 16 | $15.11 | $15.74 | $16.40 | +0.05% |
| Jul 17 | $15.03 | $15.74 | $16.48 | +0.07% |
| Jul 18 | $14.97 | $15.74 | $16.55 | +0.08% |
| Jul 19 | $14.91 | $15.74 | $16.62 | +0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $14.91 | $15.74 | $16.62 | +0.09% |
| Week 2 | $14.60 | $15.76 | $17.02 | +0.19% |
| Week 3 | $14.36 | $15.77 | $17.33 | +0.28% |
| Week 4 | $14.16 | $15.79 | $17.60 | +0.37% |
| Week 5 | $14.00 | $15.80 | $17.84 | +0.47% |
| Week 6 | $13.85 | $15.82 | $18.07 | +0.56% |
| Week 7 | $13.72 | $15.83 | $18.28 | +0.65% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rallybio Corporation is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. Its work centers on antibody-based and complement-dysregulation approaches to treat life-threatening conditions, targeting patient needs with transformative therapies.
Its lead candidate is RLYB116, an inhibitor of complement component 5 (C5) that has completed a phase 1 trial, while RLYB332 is a preclinical antibody for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company also maintains strategic alliances, including an alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as a collaboration with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio was founded in 2018 and is headquartered in New Haven, Connecticut.
Rallybio Corporation, ticker RLYB, operates in the Healthcare sector. The stock is currently priced at $15.82 per share and has a market capitalization of $91.73M, with a market ranking of 4266.
The forecasted price trajectory spans 2026 to 2050, showing a neutral start in 2026 (avg $15.82, min $4.33, max $21.06; ROI 0; sentiment NEUTRAL) and progressively bullish momentum in later years. Notable milestones include 2027 avg $20.62 (ROI 30.4%), 2028 avg $22.43 (ROI 41.8%), 2029 avg $25.41 (ROI 60.7%), and 2030 avg $33.00 (ROI 108.6%). The long-range outlook rises to 2040 avg $101.83 (ROI 543.9%) and 2050 avg $246.47 (ROI 1458.5%), all with bullish sentiment.
A major floor 48.9% below — a decisive break under it would weaken the trend.
The nearest floor, 8.1% below — buyers have tended to step in here.
The nearest ceiling, 7.2% above — a clean break opens room to run.
A major ceiling 15.0% above — clearing it would confirm fresh momentum.
Key RLYB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RLYB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $15.73 | Buy | $15.76 | Sell |
| MA 10 | $15.84 | Sell | $15.80 | Sell |
| MA 20 | $15.86 | Sell | $15.72 | Buy |
| MA 50 | $14.98 | Buy | $14.48 | Buy |
| MA 100 | $11.68 | Buy | $12.31 | Buy |
| MA 200 | $8.41 | Buy | $9.91 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.18 | Neutral |
| Stoch RSI (14) | 5.39 | Buy |
| CCI (20) | -84.54 | Neutral |
| Williams %R (14) | -84.62 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | 0.19 | Buy |
| Bollinger %B (20,2) | 0.22 | Neutral |
| Stochastic %K (14) | 15.38 | Buy |
| TRIX (15) | 0.34 | Buy |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 36.57 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 15.69 | Buy |
| ADX (14) | 24.28 | Buy |
| ATR (14) | 0.16 | Info |
The near-term technical picture is bullish, with RSI14 at 60 indicating positive momentum and a price trend above key moving averages. The 50-day simple moving average is $14.27, while the 200-day simple moving average sits at $8.13, suggesting an upward drift.
The stock trades within a 30-day range of $13.52 to $18.50, with immediate support at $14.46 and resistance at $16.87. These levels provide a framework for short-term trading and risk management given the current volatility profile (annualized volatility around 50%).
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.33 | $15.73 | $20.20 | 0% | Neutral | |
| $15.43 | $18.94 | $24.37 | +20% | Bullish | |
| $15.66 | $19.63 | $25.99 | +25% | Bullish | |
| $16.36 | $20.84 | $28.24 | +33% | Bullish | |
| $19.27 | $24.92 | $34.42 | +58% | Bullish | |
| $21.44 | $28.09 | $39.46 | +79% | Bullish | |
| $24.43 | $32.41 | $46.22 | +106% | Bullish | |
| $27.31 | $36.66 | $52.99 | +133% | Bullish | |
| $27.25 | $36.97 | $54.14 | +135% | Bullish | |
| $28.39 | $38.93 | $57.67 | +147% | Bullish | |
| $41.99 | $60.32 | $93.96 | +283% | Bullish | |
| $81.76 | $127.00 | $212.98 | +707% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.33 | $15.73 | $18.54 | +0.00% |
| August 2026 | $13.22 | $15.50 | $18.58 | -1.46% |
| September 2026 | $13.51 | $15.92 | $19.25 | +2.72% |
| October 2026 | $13.86 | $16.41 | $19.98 | +3.07% |
| November 2026 | $13.75 | $16.34 | $20.02 | -0.41% |
| December 2026 | $13.75 | $16.40 | $20.20 | +0.34% |
Click any year to see its month-by-month RLYB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RLYB is projected to trade between $4.33 and $20.20, averaging $15.73 — a potential gain of 0% from today's $15.73. Price action looks broadly range-bound.
Rallybio Corporation's 2027 outlook centres on $18.94, within a $15.43 to $24.37 range. That is up +20% on the projected 2026 average. That marks a +20% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, RLYB could reach as high as $25.99, with a base case around $19.63 and support toward $15.66 — roughly +25% from $15.73. Momentum favours further upside here.
Expect RLYB to range from $16.36 to $28.24 through 2029. The $20.84 average target implies a +33% move from current prices. That is up +6% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The RLYB price prediction for 2030 points to an average of $24.92 (low $19.27, high $34.42) — a potential gain of +58% on today's $15.73. Momentum favours further upside here.
In 2031, RLYB is projected to trade between $21.44 and $39.46, averaging $28.09 — a potential gain of +79% from today's $15.73. That is up +13% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Rallybio Corporation's 2032 outlook centres on $32.41, within a $24.43 to $46.22 range. That is up +15% on the projected 2031 average. That marks a +106% change versus current levels. Momentum favours further upside here.
By 2033, RLYB could reach as high as $52.99, with a base case around $36.66 and support toward $27.31 — roughly +133% from $15.73. Buyers look set to stay in control over this stretch.
Expect RLYB to range from $27.25 to $54.14 through 2034. The $36.97 average target implies a +135% move from current prices. That is up +1% on the projected 2033 average. Momentum favours further upside here.
The RLYB price prediction for 2035 points to an average of $38.93 (low $28.39, high $57.67) — a potential gain of +147% on today's $15.73. Buyers look set to stay in control over this stretch.
In 2040, RLYB is projected to trade between $41.99 and $93.96, averaging $60.32 — a potential gain of +283% from today's $15.73. That is up +55% on the projected 2035 average. Momentum favours further upside here.
Rallybio Corporation's 2050 outlook centres on $127.00, within a $81.76 to $212.98 range. That is up +111% on the projected 2040 average. That marks a +707% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in RLYB today (≈ 63.572791 RLYB) could be worth
$8,073.49
+$7,073.49 (+707%) by 2050 · US Dollar
Based on the average projected RLYB price of $127 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RLYBwould be worth at today's price.
$1,000 invested in RLYB on Jul 10, 2025 (≈ 315.656567 RLYB) would be worth
$4,965.28
+$3,965.28 (+396.5%) today · 4.97× · US Dollar
Based on a RLYB entry price of $3.17 vs. today's $15.73.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $15.81 | $994.63 | -0.5% |
| 1 month ago | $15.94 | $986.83 | -1.3% |
| 3 months ago | $8.44 | $1,863.74 | +86.4% |
| 6 months ago | $5.81 | $2,708.33 | +170.8% |
| 1 year ago | $3.17 | $4,965.28 | +396.5% |
| All time (5.0y) ago | $112.8 | $139.45 | -86.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RLYB forecast.
Our base-case forecast reaches $31.00 around 2032.
Implied market cap at $31.00: $179.8M
Year-by-year forecasts show a path of sustained upside after 2026, with a progression from neutral to bullish momentum. The 2027 avg is $20.62 (ROI 30.4%), expanding to 2028 $22.43 (ROI 41.8%) and 2029 $25.41 (ROI 60.7%), then 2030 at $33.00 (ROI 108.6%). The long-range view projects substantial upside, with 2040 avg $101.83 (ROI 543.9%) and 2050 avg $246.47 (ROI 1458.5%), all under a bullish sentiment.
These figures are estimates and not guarantees; actual results may differ. Investors should consider the inherent uncertainty in long-term forecasts and the impact of clinical and regulatory developments on the stock’s trajectory.
Tap a question to reveal the answer.
The forecast shows a 2030 avg of $33.00, with min $25.00 and max $46.75, ROI 108.6%, sentiment bullish.
The forecast indicates bullish sentiment from 2027 onward with rising averages and ROIs (2027 avg $20.62; 2028 $22.43; 2029 $25.41; 2030 $33.00; 2040 $101.83; 2050 $246.47), though 2026 is neutral with ROI 0. These are estimates, not guarantees.
Yes. The 2040 forecast shows an average of $101.83 and a max of $165.08, with a 543.9% ROI, indicating a potential average price above $100.
Current price is $15.82 and market cap is $91.73M.
The 30-day range is $13.52 to $18.50.
Rallybio Corporation Community Discussion
0Share your Rallybio Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.